Vol. 2 No. 1 (2022)
Reimbursement Reviews

Romosozumab (Evenity)

Published January 19, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses romosozumab (Evenity), 105 mg/1.17 mL solution for subcutaneous injection, single-use pre-filled syringe.
  • Indication: For the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture.